Carbamazepine-induced Stevens-Johnson Syndrome treated with IV steroids and IVIG

Pediatric Neurology

Volumn 22, Issue 3, 2000, Pages 231-233

  Straussberg, Rachel ^a   Harel, Liora ^a   Ben Amitai, Dan ^b   Cohen, Danielle ^c   Amir, Jacob ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b Dermatol Clin Schneider C   (Israel)

^c Kupat Holim Mahane Yehuda   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADOLESCENT; ARTICLE; CASE REPORT; CONJUNCTIVITIS; DRUG HYPERSENSITIVITY; ERYTHRODERMA; FEMALE; HUMAN; PRIORITY JOURNAL; RASH; STEVENS JOHNSON SYNDROME; TONIC CLONIC SEIZURE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; CARBAMAZEPINE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; METHYLPREDNISOLONE; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 0034060547     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(99)00137-X     Document Type: Article

References (14)

1. Shear N.H., Speilberg S.P. Anticonvulsant hypersensitivity syndrome In vitro assessment of risk . J Clin Invest. 82:1988;1826-1832.
2. Handfield-Jones S.E., Jenkins R.E., Whittaker S.J., Besse C.P., McGibbon D.H. The anticonvulsant hypersensitivity syndrome. Br J Dermatol. 129:1993;175-177.
3. Schlesinger R.G., Shear N.H. Antiepileptic drug hypersensitivity syndrome. Epilepsia. 39:1998;S3-S7.
4. Gabriel M.L. Acute management of hypersensitivity reactions and seizures. Epilepsia. 39:1998;S17-S21.
5. Faught E., Morris G., Jacobson M., et al. Adding lamotrigine to valproate Incidence of rash and other adverse effects . Epilepsia. 40:1999;1135-1140.
6. Kakourou T., Klontza D., Soteropoulou F., Katamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. Eur J Pediatr. 156:1997;90-93.
7. Patterson R., Grammer L.C., Greenberger P.A., et al. Stevens-Johnson syndrome Effectiveness of corticosteroids in management and recurrent SJS . Allergy Proc. 13:1992;289-295.
8. Patterson R., Miller M., Kaplan M., et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome Experience with 21 cases and a hypothesis regarding pathogenesis . Ann Allergy. 73:1994;27-34.
9. Cheriyan S., Patterson R., Greenberger P.A., Grammer L.C., Lattal J. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc. 4:1995;151-155.
10. Kim P.S., Goldfarb J.W., Gaisford J.W., Slater H. Stevens-Johnson syndrome and toxic epidermal necrolysis A pathological review with recommendation for a treatment protocol . J Burn Care Rehabil. 4:1983;91-100.
11. Guibal G., Bastuji-Garin S., Chosidow O., Saiag P., Revuz J., Roujeau J.C. Characteristics of toxic epidermal necrolysis in patients undergoing long term glucocorticoid therapy. Arch Dermatol. 131:1995;669-672.
12. Moudgil A., Porat S., Brunnel P., Jordan S.C. Treatment of Stevens-Johnson syndrome with pooled human intravenous immuneglobulin. Clin Pediatr. 34:1995;48-51.
13. Amato G.M., Travia A., Zino O. Impiego delle immunoglobuline endovena ad alte dosi (IGEV) in un caso di sindrome di Stevensons-Johnson. Pediatr Med Chir (Med sur Ped). 14:1992;555-556.
14. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 282:1998;490-493.